Clinical trials: Neoplasms, Solid Tumor
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cancer
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
Background: Researchers want to study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Cancer
- Trial name
- NCT03189108
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Stage IV Pancreatic Cancer
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
In this study we aim to test the efficacy of a combined and novel approach including induction chemotherapy (per standard of care) followed by SBRT and maintenance ipililumab + nivolumab in the first line setting of stage IV…
- Trial name
- NCT05088889
- Testing
- Nivolumab, ipilimumab, Stereotactic body radiation therapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Sheba Medical Center
Malignant Solid Tumors
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.
- Trial name
- NCT05508620
- Testing
- Sirolimus for Injection (Albumin-bound)
- Volunteers
- 270 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy.
- Trial name
- NCT05388058
- Testing
- Cannabidiol, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting.
- Trial name
- NCT00880191
- Testing
- dexamethasone, gabapentin
- Where
- 247 sites in United States
- Volunteers
- 430 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT07259304
- Testing
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 173 people
- Sponsor
- University of Southern California
Solid Tumors
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or…
- Trial name
- NCT03539484
- Testing
- RO7172508, Obinutuzumab, Tocilizumab
- Where
- 6 sites in Belgium, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00045448
- Testing
- alvocidib, docetaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Solid Tumor
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
This is a single center, open-label, nonrandomized, Phase 1b, dose-escalation study designed to determine maximum tolerated dose (MTD) of CKD-516 in combination with durvalumab and evaluate the safety and tolerability profile…
- Trial name
- NCT04696848
- Testing
- CKD-516 plus Durvalumab
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Tae Won Kim
Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects…
- Trial name
- NCT07123415
- Testing
- APX-343A, Pembrolizumab
- Where
- 3 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Aptabio Therapeutics, Inc.
Solid Tumors
Trial of PBI-05204 in Advanced Cancer Patients
The goal of this clinical research study is to find the highest safe dose of PBI-05204 that can be given to patients with advanced solid tumors.
- Trial name
- NCT00554268
- Testing
- PBI-05204
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005068
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Sponsor
- Mayo Clinic
Lymphoma, Refractory Solid Tumors
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132.
- Conditions
- Lymphoma, Refractory Solid Tumors, Advanced Cancer
- Trial name
- NCT02383368
- Testing
- ASP4132
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
This is an intermediate patient expanded access protocol for treatment of patients with local or metastatic solid tumors with a neoantigen synthetic long peptide vaccine.
- Trial name
- NCT06963697
- Testing
- Personalized Synthetic Long Peptide Vaccine
- Where
- United States
- Sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Neoplasms
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Primary objectives of this study are to assess the safety and tolerability of BAY 1163877 in Japanese subjects with refractory, locally advanced or metastatic solid tumors and to characterize the PK of BAY 1163877
- Trial name
- NCT02592785
- Testing
- BAY1163877
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Bayer
Advanced Solid Tumor
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose…
- Trial name
- MINOTAUR (NCT05147350)
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 38 people
- Sponsor
- Debiopharm International SA
Neoplasms
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Open label, phase I-II study to evaluate the safety and activity of intratumoral urelumab combined with systemic nivolumab in patients with advanced solid tumors.
- Trial name
- INTRUST (NCT03792724)
- Testing
- Urelumab + Nivolumab
- Where
- 2 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Solid Tumor
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Primary Objective: To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).
- Trial name
- NCT01585623
- Testing
- SAR302503, omeprazol, metoprolol
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.